TransCode Therapeutics to Host First R&D Webcast Highlighting Phase 2a Oncology Program

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced it will host its first live virtual R&D webcast on June 18, 2026, to provide strategic, scientific and clinical updates across its development pipeline. The presentation will be anchored by the company's recently initiated Phase 2a clinical trial of TTX-MC138 in circulating tumor DNA-positive colorectal cancer and will also include portfolio updates and discussion of its broader investment thesis.

The webcast marks a significant milestone for TransCode as it advances its lead therapeutic candidate, TTX-MC138, which targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. The Phase 2a trial represents a critical step in validating the company's RNA therapeutic platform, which aims to address high-risk and advanced cancers with limited treatment options. According to the press release, the company will also provide updates on its broader pipeline of first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.

This announcement is important for investors and the oncology community as it provides insight into TransCode's clinical progress and strategic direction. The company's focus on microRNA-10b as a target is particularly noteworthy, as this biomarker is associated with aggressive metastatic disease, a leading cause of cancer-related deaths. By hosting the webcast, TransCode aims to communicate the scientific rationale behind its approach and the potential implications for patients with advanced cancers.

For more details, the full press release is available at https://ibn.fm/u5AfW. Additionally, the latest news and updates relating to RNAZ can be found in the company's newsroom at https://ibn.fm/RNAZ.

TransCode Therapeutics is a clinical stage company pioneering immuno-oncology and RNA therapeutic treatments for high risk and advanced cancers. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.

The webcast is expected to draw attention from analysts and investors interested in the RNA therapeutics space, as TransCode's progress could signal broader applicability of its platform for other cancer types. The Phase 2a trial results, once available, will be pivotal in determining the efficacy of TTX-MC138 and could influence future development strategies. As such, the June 18 webcast serves as a key opportunity for stakeholders to assess the company's trajectory and the potential impact of its technology on cancer treatment.